Patents Issued in October 1, 2020
  • Automated Systems and Methods for Cell Culturing
    Publication number: 20200308532
    Abstract: Systems and methods for automated cell culturing are disclosed. The system includes a stand-alone device including a culturing vessel and an integrated controller for delivering fluids at pre-determined times and sensors for monitoring the conditions of the culturing environment. The sensors for monitoring the conditions are coupled to the controller.
    Type: Application
    Filed: March 25, 2020
    Publication date: October 1, 2020
    Inventors: Christopher J. Wegener, Alaina Schlinker
  • ACOUSTIC PERFUSION DEVICES
    Publication number: 20200308533
    Abstract: Acoustic perfusion devices for separating biological cells from other material in a fluid mixture are disclosed. The devices include an inlet port, an outlet port, and a collection port that are connected to an acoustic chamber. An ultrasonic transducer creates an acoustic standing wave in the acoustic chamber that permits a continuous flow of fluid to be recovered through the collection port while keeping the biological cells within the acoustic chamber to be returned to the bioreactor from which the fluid mixture is being drawn.
    Type: Application
    Filed: May 21, 2020
    Publication date: October 1, 2020
    Inventors: Bart Lipkens, Erik Miller, Benjamin Ross-Johnsrud, Walter M. Presz, JR., Kedar Chitale, Thomas J. Kennedy, III, Lauryn Winiarski
  • RECOMBINANT URICASE ENZYME
    Publication number: 20200308534
    Abstract: Disclosed are recombinant mutant Candida utilis uricase enzymes with improved pancreatin stability and/or activity, compositions containing such uricase enzymes, which can be used, among other things, to treat diseases or disorders associated with an elevated amount of uric acid, including, for example, hyperuricemia, hyperuricosuria, and gout.
    Type: Application
    Filed: July 6, 2018
    Publication date: October 1, 2020
    Applicant: Allena Pharmaceuticals, Inc.
    Inventors: Aditi R. DESHPANDE, Danica GRUJIC, Sridhar GOVINDARAJAN, Mark WELCH
  • PSEUDOMONAS AERUGINOSA WITH MONOMETHYLAMINE DEGRADABILITY AND APPLICATION THEREOF
    Publication number: 20200308535
    Abstract: The present invention discloses a strain of Pseudomonas aeruginosa with monomethylamine degradability and the application thereof. This strain, named Pseudomonas aeruginosa GDUTAN1, was deposited on May 24, 2017 in the China Center for Type Culture Collection in Wuhan University, Wuhan City, Hubei Province with a deposit number of CCTCC NO.: M 2017283. This Pseudomonas aeruginosa GDUTAN1 was Gram-negative and rod-like, and round, green and opaque in the colony morphology, having a diameter of 1-2 mm. The Pseudomonas aeruginosa GDUTAN1 of the present invention can be applied to environmental remediation, degrading monomethylamine in the environment at a high degradation efficiency. When it degrades monomethylamine for 96 h at a substrate concentration of 50-140 mg/L, the degradation efficiency can reach more than 99%.
    Type: Application
    Filed: March 20, 2018
    Publication date: October 1, 2020
    Inventors: TAICHENG AN, SHIAI LI, GUIYING LI
  • CELL CULTURE METHODS
    Publication number: 20200308536
    Abstract: The present invention relates to methods for reducing the heterogeneity of a population of recombinant proteins produced in cell culture, said methods comprising growing host cells producing a recombinant protein in a cell culture medium wherein the cell culture medium comprises one or more cysteine/cystine analogs.
    Type: Application
    Filed: November 29, 2018
    Publication date: October 1, 2020
    Inventors: VALENTINE CHEVALLIER, NADINE KOCHANOWSKI, LAETITIA MALPHETTES, VINCENT ADOLPHE CAROL COOL
  • CELL CULTURE MEDIUM COMPRISING SMALL PEPTIDES
    Publication number: 20200308537
    Abstract: Cell culture media, concentrated media and feeds, methods of manufacturing cell culture media and feeds, and methods of culturing cells are provided. One or more small peptides, including dipeptides are added to the cell culture media to provide improved stability and improved conditions for culturing cells.
    Type: Application
    Filed: June 16, 2020
    Publication date: October 1, 2020
    Inventors: Shawn BARRETT, Scott JACOBIA
  • COMPOSITIONS AND METHODS FOR TREATING LIVER DISEASE AND DYSFUNCTION
    Publication number: 20200308538
    Abstract: The invention features compositions and methods that are useful for generating human hepatocyte-like cells (HLCs) and methods of using such cells for the treatment of diseases associated with a loss in liver cell number or function.
    Type: Application
    Filed: September 10, 2018
    Publication date: October 1, 2020
    Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., VIRGINIA COMMONWEALTH UNIVERSITY
    Inventors: ROBERT A. FISHER, GIUSEPPE PETTINATO
  • AFFINITY-TAGGED PHOTOSWITCHES AND METHODS OF USE THEREOF
    Publication number: 20200308539
    Abstract: The present disclosure provides a conjugate comprising: a) an affinity agent that specifically binds a target ligand-binding polypeptide; and b) a photoisomerizable regulator comprising: i) a photoisomerizable moiety; and ii) a ligand that binds to the target ligand-binding polypeptide. The present disclosure provides cells comprising a conjugate of the present disclosure. The present disclosure provides methods of using a conjugate of the present disclosure to modulate activity of a target polypeptide, and to modulate activity of a target cell or cell population.
    Type: Application
    Filed: September 21, 2018
    Publication date: October 1, 2020
    Inventors: Ehud Y. Isacoff, Dirk Trauner, Johannes Broichhagen, Joshua Levitz
  • METHODS OF MAKING, EXPANDING, AND USING A HUMAN PROGENITOR T CELL
    Publication number: 20200308540
    Abstract: A CD7+ progenitor T cell, a method of producing the CD7+ progenitor T cell, and a method of administering the CD7+ progenitor T cell. The method of producing the CD7+ progenitor T cell includes expanding CD34+ cells.
    Type: Application
    Filed: September 28, 2018
    Publication date: October 1, 2020
    Inventors: Heather Emily Stefanski, John Edward Wagner, Jr., Bruce Robert Blazar, Jastaranpreet Singh, Juan Carlos Zúñiga-Pflücker
  • Compound Chimeric Antigen Receptor (CCAR) Targeting Multiple Antigents, Compositions and Methods of Use Thereof
    Publication number: 20200308541
    Abstract: In one embodiment, the present disclosure provides an engineered cell having a first chimeric antigen receptor polypeptide including a first antigen recognition domain, a first signal peptide, a first hinge region, a first transmembrane domain, a first costimulatory domain, and a first signaling domain; and a second chimeric antigen receptor polypeptide including a second antigen recognition domain, a second signal peptide, a second hinge region, a second transmembrane domain, a second co-stimulatory domain, and a second signaling domain; wherein the first antigen recognition domain is different than the second antigen recognition domain.
    Type: Application
    Filed: October 12, 2018
    Publication date: October 1, 2020
    Inventors: Yupo Ma, Kevin PINZ, Xun Jiang, Masayuki Wada, Kevin Chen
  • REGULATORY T CELL EPITOPES
    Publication number: 20200308542
    Abstract: The present is directed to compositions comprising regulatory T cell epitopes, wherein said epitopes comprise a polypeptide comprising at least a portion of SEQ NOS: 1-14, fragments and/or variants thereof, as well as methods of producing and using the same.
    Type: Application
    Filed: October 5, 2018
    Publication date: October 1, 2020
    Inventors: William Martin, Amy S. Rosenberg
  • METHODS FOR OBTAINING REGULATORY T CELLS AND USES THEREOF
    Publication number: 20200308543
    Abstract: Disclosed is a method for obtaining a population of human Treg cells including the steps of: (a) culturing a population of human monocytes with a medium including an amount of an interleukin-34 (IL-34) polypeptide in order to obtain a population of immunosuppressive macrophages; (b) co-culturing a population of human peripheral blood mononuclear cells (PBMCs) and the population of immunosuppressive macrophages obtained at step (a).
    Type: Application
    Filed: June 11, 2020
    Publication date: October 1, 2020
    Inventors: Carole GUILLONNEAU, Ignacio ANEGON, Severine BEZIE
  • METHODS AND PRODUCTS FOR TRANSFECTING CELLS
    Publication number: 20200308544
    Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.
    Type: Application
    Filed: May 7, 2020
    Publication date: October 1, 2020
    Inventors: Matthew ANGEL, Christopher ROHDE
  • CONDITIONALLY IMMORTALIZED LONG-TERM STEM CELLS AND METHODS OF MAKING AND USING SUCH CELLS
    Publication number: 20200308545
    Abstract: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.
    Type: Application
    Filed: June 15, 2020
    Publication date: October 1, 2020
    Inventors: John C. CAMBIER, Yosef REFAELI, Sara Ann JOHNSON, Brian Curtis TURNER
  • ENGINEERED CARDIOMYOCYTES AND USES THREOF
    Publication number: 20200308546
    Abstract: The present disclosure provides the development of engineered cardiomyocytes having mutations in transcription factor involved in vivo with cardiac development and/or function. These cell populations comprise mutations that are associated with deleterious effects in vivo in mammals. The mutations of the engineered cardiomyocytes of the disclosure thus are rationally designed based on demonstrated physiological effects in mammals, e.g., mice or humans.
    Type: Application
    Filed: June 27, 2017
    Publication date: October 1, 2020
    Applicant: The J. David Gladstone Institutes, A Testamentary Trust Established Under the Will of Will of J. Dav
    Inventors: Deepak SRIVASTAVA, Yen-Sin ANG
  • STEM CELL CONDITIONED MEDIA AND METHODS OF PRODUCING THE SAME
    Publication number: 20200308547
    Abstract: Stem cell conditioned media and methods of producing the same to treat mammalian injuries or insults. In at least one embodiment of a method of producing a stem cell conditioned media of the present disclosure, the method comprises the steps of culturing at least one stem cell in a first cell culture medium, replacing some or all of the first cell culture medium with a second cell culture medium and further culturing the at least one stem cell in the second cell culture medium, and collecting a quantity of the second cell culture medium after a culture duration, wherein the quantity of the second cell culture medium contains a cell culture byproduct effective to treat a mammalian insult or injury. A stem cell culture supernatant containing at least one factor capable of exerting effective neuroprotection to treat a mammalian neural injury or insult.
    Type: Application
    Filed: June 16, 2020
    Publication date: October 1, 2020
    Applicant: NeuroFx, Inc.
    Inventors: Keith Leonard March, Brian H. Johnstone, Yansheng Du
  • Amplifying Beta Cell Differentiation with Small Molecules BET (Bromodomain And Extraterminal Family Of Bromodomain-Containing Proteins) Inhibitors
    Publication number: 20200308548
    Abstract: The present invention provides an in vitromethod for obtaining cells of the pancreatic endocrine lineage, comprising a step of culturing pancreatic progenitor cells, wherein said pancreatic progenitor cells are in a cell culture medium comprising at least one BET inhibitor.
    Type: Application
    Filed: June 30, 2017
    Publication date: October 1, 2020
    Inventors: Lukas Huijbregts, Raphael Scharfmann, Christian Honore
  • Biosensors in Human Gut Organoids
    Publication number: 20200308549
    Abstract: Ex vivo monolayer models of human interstinal epithelia that express sensors, and methods of use thereof for evaluation of the effects of test compounds on the human gut.
    Type: Application
    Filed: March 30, 2020
    Publication date: October 1, 2020
    Inventors: Alessio Fasano, Timothy K. Lu, Stefania Senger, Maria Eugenia Inda
  • TUMOR ORGANOID MODEL
    Publication number: 20200308550
    Abstract: A method of generating an artificial 3D tissue culture of a cancer grown in non-cancerous tissue, includes the steps of providing an aggregate of pluripotent stem cells or progenitor cells, culturing and expanding the cells in a 3D biocompatible matrix, wherein the cells are allowed to differentiate to develop the aggregate into a tissue culture of a desired size; wherein at least a portion of the cells are subjected to cancerogenesis by expressing a oncogene and/or by suppressing a tumor suppressor gene during any of the steps or in the tissue culture, and further including the step of allowing the cells with an expressed oncogene or suppressed tumor suppressor to develop into cancerous cells; drug screening methods; oncolytic virus screening methods; a 3D tissue culture; and a kit for performing the inventive methods.
    Type: Application
    Filed: September 11, 2018
    Publication date: October 1, 2020
    Inventors: Jürgen KNOBLICH, Shan BIAN
  • METHODS FOR PRODUCING HEPATOCYTES
    Publication number: 20200308551
    Abstract: Methods for producing hepatocytes from pluripotent human stem cells are disclosed herein. The stem cells are plated on a cell culture substrate comprising two laminins. The stem cells are then exposed to different cell culture mediums to induce differentiation. The resulting hepatocytes have higher metabolic capacity compared to hepatocytes cultured on different substrates.
    Type: Application
    Filed: June 16, 2020
    Publication date: October 1, 2020
    Inventors: Louise Kristina Hagbard, Carl Gunnar Jesper Ericsson, Katherine Rachel Cameron, David Colin Hay, Stuart John Forbes, Hassan Rashidi
  • Expression Cassette
    Publication number: 20200308552
    Abstract: Disclosed is an expression cassette comprising, in a 5? to 3? direction of a sense strand, a promoter, and a first nucleic acid, a terminator and a second nucleic acid operably linked to the promoter, wherein the first nucleic acid and the second nucleic acid each contain at least one gene.
    Type: Application
    Filed: September 28, 2018
    Publication date: October 1, 2020
    Applicant: Spiber Inc.
    Inventor: Masahiro Murakami
  • AAV VECTORS
    Publication number: 20200308553
    Abstract: The present invention relates to an adeno-associated virus (AAV), comprising an insertion of at least 6-8 amino acids between the positions corresponding to position 587 and 588 of SEQ ID NO: 1. Also envisioned are AAVs of the present invention for use as a medicament and pharmaceutical compositions comprising the AAV of the present invention. Further, the present invention relates to an in vitro use of AAV of the present invention for transduction of the nucleus of retinal cells. Also concerned is a method for screening an insertion sequence as well as a peptide obtainable by the method for screening. Also contemplated are kits comprising the AAV of the present invention.
    Type: Application
    Filed: October 16, 2018
    Publication date: October 1, 2020
    Inventors: Stylianos Michalakis, Martin Biel
  • GENE THERAPIES FOR LYSOSOMAL DISORDERS
    Publication number: 20200308554
    Abstract: The disclosure relates, in some aspects, to compositions and methods for treatment of diseases associated with aberrant lysosomal function, for example Parkinson's disease (PD) and Gaucher disease. In some embodiments, the disclosure provides expression constructs comprising a transgene encoding beta-Glucocerebrosidase (GBA) or a portion thereof alone or in combination with one or more PD-associated genes. In some embodiments, the disclosure provides methods of Parkinson's disease by administering such expression constructs to a subject in need thereof.
    Type: Application
    Filed: June 18, 2020
    Publication date: October 1, 2020
    Inventors: Asa ABELIOVICH, Laura HECKMAN, Herve RHINN
  • LASSA VACCINE
    Publication number: 20200308555
    Abstract: The invention relates to recombinant measles virus expressing Lassa virus polypeptides, and concerns in particular immunogenic LASV particles expressed by a measles virus and/or virus like particles (VLPs) that contain proteins of a Lassa virus. These particles are recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acid constructs, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by Lassa virus.
    Type: Application
    Filed: December 20, 2018
    Publication date: October 1, 2020
    Inventors: Mathieu MATEO, Sylvain BAIZE, Frédéric TANGY
  • ORNITHINE TRANSCARBAMYLASE CODING POLYRIBONUCLEOTIDES AND FORMULATIONS THEREOF
    Publication number: 20200308556
    Abstract: In certain aspects, the disclosure relates to compositions comprising modified Ornithine transcarbamylase (OTC) polyribonucleotides and methods of use.
    Type: Application
    Filed: December 15, 2017
    Publication date: October 1, 2020
    Inventors: Carsten Rudolph, Rebekka Kubisch-Dohem, Manish Kumar Aneja, Johannes Geiger, Marino Schuhmacher
  • FUSION PROTEINS
    Publication number: 20200308557
    Abstract: Provided are fusion target-binding proteins comprising a target binding moiety, an intracellular signalling region and a domain that promotes synthesis of arginine or an arginine precursor. The domain may be an enzyme domain such as an argininosuccinate synthase (ASS-1) enzyme domain, or an ornithine transcarbamylase (OTC) enzyme domain. Also provided are cells comprising such a fusion target-binding protein (for example cells that express the fusion target-binding protein), and nucleic acids encoding such fusion target-binding proteins. The invention also provides fusion target-binding proteins comprising a target binding moiety, an intracellular signalling region and a domain that promotes synthesis of tryptophan or a tryptophan precursor. Pharmaceutical compositions, medical uses, and methods of treatment, all using the fusion target-binding proteins, cells, or nucleic acids are disclosed.
    Type: Application
    Filed: December 24, 2018
    Publication date: October 1, 2020
    Applicant: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Francis Jay Mussai, Carmela De Santo, Steven Lee
  • METHODS FOR USING PHYTASE IN ETHANOL PRODUCTION
    Publication number: 20200308558
    Abstract: The present disclosure relates to methods for using one or more polypeptides with phytase activity in grain processing, ethanol, and biofuel production.
    Type: Application
    Filed: March 3, 2017
    Publication date: October 1, 2020
    Inventors: Danielle CUSUMANO, Tony NEWTON, Arne I. SOLBAK
  • Composition for detecting protein-protein interactions comprising fragments of secreted alkaline phosphatase (SEAP) and method for detecting protein-protein interactions using the same
    Publication number: 20200308559
    Abstract: Provided are a composition for detecting protein-protein interactions comprising fragments of secreted alkaline phosphatase (SEAP) and a method for detecting protein-protein interactions using the same. According to the composition or the method of the present invention, it is possible to simply detect the protein-protein interactions in the cells without environmental changes (e.g., cell destruction) in the cells. Furthermore, the composition or the method of the present invention can also be used for detection of materials that enhance or inhibit protein-protein interactions.
    Type: Application
    Filed: November 25, 2019
    Publication date: October 1, 2020
    Inventor: Tae Uk KIM
  • NOVEL TYPE VI CRISPR ORTHOLOGS AND SYSTEMS
    Publication number: 20200308560
    Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a novel RNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA.
    Type: Application
    Filed: June 26, 2018
    Publication date: October 1, 2020
    Inventors: Feng Zhang, Omar O. Abudayyeh, David Benjamin Turitz Cox, Jonathan S. Gootenberg
  • CAS9 VARIANTS AND METHODS OF USE
    Publication number: 20200308561
    Abstract: Compositions and methods are provided for variant Cas systems and elements comprising such systems, including, but not limiting to, Cas endonuclease variants, guide polynucleotide/Cas endonuclease complexes comprising Cas endonuclease variants, as well as guide polynucleotides and guide RNA elements that can interact with Cas endonuclease variants. Compositions and methods are provided for genome modification of a target sequence in the genome of a cell. The methods and compositions employ a guide polynucleotide/Cas endonuclease system comprising a Cas9 endonuclease variant to provide an effective system for modifying or altering target sequences within the genome of a cell or organism.
    Type: Application
    Filed: December 11, 2018
    Publication date: October 1, 2020
    Inventors: Ryan L. Frisch, Hongxian He
  • SIMULTANEOUS MULTIPLEX GENOME EDITING IN YEAST
    Publication number: 20200308562
    Abstract: The present disclosure provides compositions of matter, methods and instruments for editing nucleic acids in live yeast cells.
    Type: Application
    Filed: March 23, 2020
    Publication date: October 1, 2020
    Inventors: Miles Gander, Tian Tian, Skylar Stefani
  • ALPHA-AMYLASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME
    Publication number: 20200308563
    Abstract: The present invention relates to alpha-amylase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Application
    Filed: June 17, 2020
    Publication date: October 1, 2020
    Applicant: Novozymes A/S
    Inventors: Carsten Andersen, Signe E. Larsen, Esben Peter Friis, Pernille Ollendorff Micheelsen, Anders Viksoee-Nielsen, Randy Deinhammer, Xinyu Shen
  • METHODS AND COMPOSITIONS FOR STABILIZING TRANS-SPLICING INTEIN MODIFIED PROTEASES
    Publication number: 20200308564
    Abstract: Methods for producing a trans-splicing intein-modified protease with enhanced solubility and regulating its activity are described. Intein-modified proteases having enhanced solubility and polynucleotides encoding the same are provided. Methods of storing trans-splicing proteases are also described.
    Type: Application
    Filed: June 11, 2020
    Publication date: October 1, 2020
    Applicant: AGRIVIDA, INC.
    Inventors: R. Michael RAAB, Binzhang SHEN, Gabor LAZAR
  • SERINE PROTEASE MOLECULES AND THERAPIES
    Publication number: 20200308565
    Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.
    Type: Application
    Filed: June 15, 2020
    Publication date: October 1, 2020
    Applicant: Research Development Foundation
    Inventors: Michael G. ROSENBLUM, Khalid Amanali MOHAMEDALI, Lawrence H. CHEUNG
  • CELL CULTURE METHODS FOR EXPRESSING ADAMTS PROTEIN
    Publication number: 20200308566
    Abstract: The present invention provides culture mediums that are useful for the expression of ADAMTS proteins, such as ADAMTS13. Methods for the expression and purification of ADAMTS proteins are also provided. In some embodiments, the mediums and methods of the invention are useful for the expression of ADAMTS proteins having high specific activities. Also provided are ADAMTS, e.g., ADAMTS13, protein compositions with high specific activities, which are expressed and purified according to the methods provided herein.
    Type: Application
    Filed: June 16, 2020
    Publication date: October 1, 2020
    Inventors: Leopold Grillberger, Alexandra Spenger, Meinhard Hasslacher, Rana Grillberger, Manfred Reiter
  • CREATININE DEIMINASE AND USES THEREOF
    Publication number: 20200308567
    Abstract: The present invention relates broadly to the field of creatinine determination. In particular, it provides a novel creatinine deiminase characterized by novel nucleic acid and amino acid sequences and superior enzymatic activity. It also provides uses of this creatinine deiminase, including assays for determining the amount of creatinine in a sample. These can be useful inter alia for the detection of kidney disease.
    Type: Application
    Filed: December 20, 2018
    Publication date: October 1, 2020
    Inventor: Helmut SCHWAB
  • ALCOHOL STABLE ENZYMES
    Publication number: 20200308568
    Abstract: The present disclosure provides enzyme-polymer conjugates stable to denaturing action of alcohols and methods for using enzyme-polymer conjugates in biocatalysis.
    Type: Application
    Filed: March 24, 2020
    Publication date: October 1, 2020
    Inventors: Antonina Simakova, Gregory Lewis, Alan Russell, Krzysztof Matyjaszewski
  • METHODS AND APPARATUS FOR PURIFYING RNA
    Publication number: 20200308569
    Abstract: The invention features methods and apparatus for purifying a sample including an RNA (e.g., an RNA having a poly(A) sequence, such as an mRNA). Methods of the invention involve adding a liquid to a sample container including the sample and a solid affinity material (e.g., oligo(dT) or hydroxyapatite), agitating the contents of the sample, removing the liquid, and eluting the RNA of interest from the sample container. The apparatus of the invention include a sample container and one or more components such as a reservoir, collection container, pressure generating source, valve assembly, and agitation mechanism. Certain apparatus include a rotatable magnet or magnetizable component. The methods and apparatus described herein are useful in providing RNA (e.g., RNA having a poly(A) sequence, such as mRNA) in high yield and with high purity using less solvent than conventional purification techniques.
    Type: Application
    Filed: June 21, 2017
    Publication date: October 1, 2020
    Applicant: ModernaTX, Inc.
    Inventor: Benjamin Frank GELDHOF
  • PROCESS FOR ISOLATING NUCLEIC ACIDS FROM SAMPLE MATERIALS
    Publication number: 20200308570
    Abstract: The invention relates to a process for isolating nucleic acids, such as DNA and RNA, using a non-alcoholic and non-chaotropic binding solution, and to the binding solutions and kits suitable for such a process.
    Type: Application
    Filed: March 26, 2020
    Publication date: October 1, 2020
    Applicant: Axagarius GmbH & Co. KG
    Inventors: Andreas von Bohl, Yvonne Schuell
  • ADENINE DNA BASE EDITOR VARIANTS WITH REDUCED OFF-TARGET RNA EDITING
    Publication number: 20200308571
    Abstract: Engineered adenine base editor (ABE) variants with reduced RNA editing activity, and methods of using the same.
    Type: Application
    Filed: February 4, 2020
    Publication date: October 1, 2020
    Inventors: J. Keith Joung, Julian Grunewald, Ronghao Zhou
  • Modification of D and T Arms of tRNA Enhancing D-Amino Acid and Beta-Amino Acid Uptake
    Publication number: 20200308572
    Abstract: The purpose of the present invention is to provide, for translation in a cell-free translation system, a novel translation system capable of synthesizing a peptide having therein consecutive non-proteinogenic amino acids. The present invention provides a tRNA containing the base sequence represented by SEQ ID NO: 1 and encoding a non-proteinogenic amino acid.
    Type: Application
    Filed: August 28, 2018
    Publication date: October 1, 2020
    Inventors: Hiroaki Suga, Takayuki Katoh
  • NUCLEIC ACID-TAGGED COMPOSITIONS AND METHODS FOR MULTIPLEXED PROTEIN-PROTEIN INTERACTION PROFILING
    Publication number: 20200308573
    Abstract: Methods and compositions for multiplexed protein-protein interaction profiling (e.g., immunoprofiling), based on nucleic acid tagging of polypeptides (e.g., by RNA display)are described. In some embodiments the described compositions and methods utilize a library of prey polypeptide targets linked to prey RNAs encoding them, and a population of bait polypeptides, e.g., a mixture of antibodies, that bind to one or more of the prey polypeptide targets and are used to isolate and identify the bound prey polypeptide targets by amplification of their associated prey RNAs and sequencing of the corresponding cDNAs. In other embodiments the prey polypeptide targets are linked to DNA Bar Codes, which serve as unique identifiers of the tagged polypeptide.
    Type: Application
    Filed: June 15, 2020
    Publication date: October 1, 2020
    Inventor: Joshua LaBaer
  • LIGATION AND/OR ASSEMBLY OF NUCLEIC ACID MOLECULES
    Publication number: 20200308574
    Abstract: The present invention relates to ligation and/or assembly of nucleic acid molecules. Particularly, a double-stranded target nucleic acid having overhangs of at least one nucleotide is ligated with another nucleic acid molecule capable of forming a stem-loop structure with an overhang of at least one nucleotide. The invention is suitable for tagging nucleic acid molecules. In specific embodiments, the overhangs can be produced by chemical cleavage of phosphorothioate-modified nucleic acid molecules. The invention further relates to the amplification of the ligated product, and using the resultant amplicon for assembly of multiple nucleic acid fragments.
    Type: Application
    Filed: October 24, 2018
    Publication date: October 1, 2020
    Inventors: Kang ZHOU, Xiaoqiang MA, Hong LIANG
  • VARIANT NUCLEIC ACID LIBRARIES FOR ANTIBODY OPTIMIZATION
    Publication number: 20200308575
    Abstract: Provided herein are methods and compositions relating to libraries of optimized antibodies having nucleic acids encoding for an antibody comprising modified sequences. Libraries described herein include variegated libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein.
    Type: Application
    Filed: February 26, 2020
    Publication date: October 1, 2020
    Inventor: Aaron SATO
  • NOVEL METHOD FOR GENERATING CIRCULAR SINGLE-STRANDED DNA LIBRARIES
    Publication number: 20200308576
    Abstract: The invention is a novel method of making and using a library such as a sequencing library of single stranded circular nucleic acid templates via splint ligation.
    Type: Application
    Filed: March 3, 2020
    Publication date: October 1, 2020
    Inventors: Daleen Badenhorst, Richard Dannebaum, Ashley Hayes, Monica Herrera, Severine Margeridon, Martin Ranik
  • DNA-RESPONSIVE HYDROGELS, METHODS OF ALTERING A PROPERTY OF A HYDROGEL, AND APPLICATIONS THEREOF
    Publication number: 20200308577
    Abstract: Disclosed herein are hydrogels comprising a polynucleotide-based structural component. Methods of altering a property of a hydrogel based on user-defined nucleic acid input sequences are also disclosed. In addition, various applications are described that utilize these hydrogels and methods.
    Type: Application
    Filed: January 31, 2020
    Publication date: October 1, 2020
    Applicant: Massachusetts Institute of Technology
    Inventors: James J. Collins, Helena de Puig Guixe, Luis Soenksen Martinez, Max English, Raphael Gayet, Nicolaas Angenent-Mari, Angelo S. Mao, Peter Q. Nguyen
  • RNA DUPLEXES WITH SINGLE STRANDED PHOSPHOROTHIOATE NUCLEOTIDE REGIONS FOR ADDITIONAL FUNCTIONALITY
    Publication number: 20200308578
    Abstract: The present invention relates to RNAi constructs and their use in gene silencing. RNAi constructs associated with the invention contain a double stranded region connected to a single stranded region of phosphorothioate modified nucleotides.
    Type: Application
    Filed: November 11, 2019
    Publication date: October 1, 2020
    Applicant: PHIO PHARMACEUTICALS CORP.
    Inventors: TOD M. WOOLF, JOANNE KAMENS, WILLIAM SALOMON, ANASTASIA KHVOROVA
  • LIPOSOMAL SPHERICAL NUCLEIC ACID (SNA) CONSTRUCTS PRESENTING ANTISENSE OLIGONUCLEOTIDES (ASO) FOR SPECIFIC KNOCKDOWN OF INTERLEUKIN 17 RECEPTOR MRNA
    Publication number: 20200308579
    Abstract: Aspects of the invention relate to antisense oligonucleotides directed to the interleukin 17 receptor (IL-17R), and other targets. Spherical nucleic acid formulations or compositions of antisense oligonucleotides and related methods of treatment are also provided.
    Type: Application
    Filed: May 5, 2017
    Publication date: October 1, 2020
    Applicant: Exicure, Inc.
    Inventor: Richard Kang
  • COMBINATIONS FOR THE MODULATION OF SMN EXPRESSION
    Publication number: 20200308580
    Abstract: Certain embodiments are directed to methods and compounds for modulating expression of SMN. In certain embodiments at least two compounds are used: a first compound for inhibiting SMN-NAT and increasing expression of SMN, and a second compound for modulating the splicing of SMN. Such methods and compounds are useful for increasing expression exon 7 containing SMN mRNA in cells and animals.
    Type: Application
    Filed: June 16, 2017
    Publication date: October 1, 2020
    Applicants: Ionis Pharmaceuticals, Inc., The Johns Hopkins University
    Inventors: Frank Rigo, C. Frank Bennett, Constantin Van Outryve D'Ydewalle, Charlotte J. Sumner
  • CRISPR/CAS SYSTEM AND METHOD FOR GENOME EDITING AND MODULATING TRANSCRIPTION
    Publication number: 20200308581
    Abstract: A CRISPR/Cas system and method for editing or regulating transcription of a genome of a cell are provided, wherein the system includes a Cas endonuclease fused with one or more degron sequences and at least one activatable cognate single guide RNA harboring an inactivation sequence in a non-essential region of the cognate sgRNA, wherein said inactivation sequence comprises one or more endonuclease recognition sites of, e.g., a ribozyme.
    Type: Application
    Filed: September 21, 2018
    Publication date: October 1, 2020
    Inventors: Ryan E. Clarke, Bradley J. Merrill, Matthew S. MacDougall, Hannah M. Pennington, Brian R. Shy